Gibco rpmi media

The U2OS, U2OS Baf180 KO and Baf180sh, and U2OS reporter cell lines (U2OS 263 IFII and U2OS 265, Tang et al., 2013 (link)) were maintained in a 5% CO₂ incubator at 37°C in GIBCO DMEM media (Life Technologies, Paisley, UK) supplemented with 100 U/mL penicillin/streptomycin, 2 mM L-glutamine and 10% FCS (U2OS) or 10% TET System approved FCS (U2OS reporter cell lines; 631106, Takara Bio).
LNCaP cells were obtained from ATCC (Clone FGC, CRL-1740) and cultured in GIBCO RPMI media (Life Technologies, Paisley, UK) supplemented with 10% FCS, 2 mM L-glutamine, 100 U/mL penicillin/streptomycin, 10 mM HEPES and 1 mM sodium pyruvate. All cell lines were regularly tested for mycoplasma contamination.

The human colorectal cancer cell lines RKO and DLD1 (ATCC, LGC Standards, Middlesex, UK) and their CPT-11 resistant derivative single clones were maintained in a 5% CO₂ incubator at 37°C and grown in Gibco RPMI media (Life Technologies, Paisley, UK) supplemented with 10% FCS and 2 mM l-glutamine. Irinotecan hydrochloride (CPT-11), 5-fluorouracil (5-FU), oxaliplatin, hydroxyurea (HU), camptothecin (CPT), doxorubicin, etoposide and SN-38 were obtained from Sigma-Aldrich (Gillingham, UK) whilst the PARP inhibitor, olaparib (AZD2281) was obtained from Stratech Scientific Limited (Suffolk, UK). Trichostatin A (TSA) and Panobinostat (LBH-589) were obtained from Selleckchem.